Neulasta Onpro: a coup de grâce?

Chelsee J Jensen,Caleb J Scheckel,Ronald S Go,Aakash Desai,Scott A Soefje

The American journal of managed care（2023）

引用 0|浏览23

暂无评分

摘要

With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要